Table 1.
Patient Demographics and Baseline Characteristics
| Characteristic | Part A | Part B | Part C | Part B + Ca |
|---|---|---|---|---|
| Marizomib (N = 30) |
Marizomib + Bevacizumab (N = 36) |
Marizomib + Bevacizumab (N = 41) |
Marizomib ≤0.8 mg/m2 + Bevacizumab (N = 67) |
|
| Age, median (range), years | 58.5 (25–80) | 55 (27–76) | 56 (19–75) | 56 (27–76) |
| Female, n (%) | 13 (43.3) | 13 (36.1) | 21 (51.2) | 27 (40.3) |
| Baseline KPS score, n (%) | ||||
| 70 | 4 (13.3) | 5 (13.9) | 7 (17.1) | 12 (17.9) |
| 80 | 9 (30.0) | 14 (38.9) | 15 (36.6) | 25 (37.3) |
| 90 | 15 (50.0) | 11 (30.6) | 15 (36.6) | 21 (31.3) |
| 100 | 2 (6.7) | 6 (16.7) | 4 (9.8) | 9 (13.4) |
| Time since grade IV diagnosis, median (range), months | 10.7 (1–20) | 10.0 (2–41) | 11.2 (0.4–34.6) | 9.7 (0.4–40.7) |
| Disease status, n (%) | ||||
| Unifocal | 20 (66.7) | 31 (86.1) | 27 (65.9) | 50 (74.6) |
| Multifocal | 10 (33.3) | 5 (13.9) | 14 (34.1) | 17 (25.4) |
| EGFR variant III status, n (%) | ||||
| Positive | 2 (6.7) | 4 (11.1) | 4 (9.8) | 7 (10.4) |
| Negative | 18 (60.0) | 21 (58.3) | 29 (70.7) | 44 (65.7) |
| Missing/unknown | 10 (33.3) | 11 (30.6) | 8 (19.5) | 16 (23.9) |
| MGMT promoter methylation status, n (%) | ||||
| Methylated | 6 (20.0) | 10 (27.8) | 14 (34.1) | 21 (31.3) |
| Unmethylated | 18 (60.0) | 22 (61.1) | 21 (51.2) | 38 (56.7) |
| Missing/unknown | 6 (20.0) | 4 (11.1) | 6 (14.6) | 8 (11.9) |
| Prior therapeutic regimens, median (range), n | 1 (1‒3) | 2 (1–4) | 1 (1–4) | 1 (1–4) |
a Excluding dose-escalated patients.
EGFR, epidermal growth factor receptor; MGMT, O6-methylguanine-DNA-methyltransferase.